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abnormal (P , .02 versus any individual biomarker). Responders largely agreed that a combination
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The International Working Group [1,2] and National
Institute on Aging–Alzheimer’s Association criteria [3–5]
recognize the importance of imaging and cerebrospinal
fluid (CSF) markers for the early diagnosis of Alzheimer’s
disease (AD) at the stage of mild cognitive impairment
(MCI). The proposed criteria state that positivity on one or
more biomarkers of brain amyloidosis (decreased levels of
amyloid beta 42 (Ab42) in the CSF and increased binding
of amyloid imaging ligands on positron emission
tomography [PET]) and neuronal injury (medial temporal
atrophy [MTA] on magnetic resonance imaging (MRI),
increased total tau or phospho-tau in the CSF, and cortical
temporoparietal, and posterior cingulate cortex hypometab-
olism on fluorodeoxyglucose positron emission tomography
[FDG-PET] or if FDG-PET is unavailable, hypoperfusion on
single positron emission computed tomography [SPECT]) is
associated with a high probability that the patient’s cognitive
impairment is due to AD pathology.
The authors of the revised criteria [1–5] are cautious
regarding the use of biomarkers in the clinical practice.
They advise that these should be regarded as “research”
criteria predominantly, although they may be applicable in
some specialized clinical services with appropriateknowledge and facilities. The revised criteria were
developed on the basis of scientific evidence from the
literature, although they still have limitations being based
on available studies, such as study design heterogeneity
(i.e. population, follow-up time, cut-off and normative
values, and lack of Standard Operating Procedures [SOPs]
for biomarker assessment) [6]. Importantly, the criteria still
need to be properly validated, implying that a large body of
empirical evidence still needs to be collected to show that,
when applied following appropriate SOPs, the proposed
combinations of biomarkers enhance diagnostic accuracy.
Some structured programs are currently ongoing where
MCI patients are assessed by traditional clinical assessment
supportedbyanextended rangeof core biomarkers that include
MTA, CSFAb/tau, and hypometabolismon FDG-PET [7–10].
However, these programs are constrained to a limited number
of academic memory clinics, whereas the measurement of
individual biomarkers are now available to and used by a
much larger number of memory clinics with a clinical
research background, including those of the European
Alzheimer’s Disease Consortium (EADC, http://www.eadc.
info). While validation of the revised diagnostic criteria is
still awaited and large cases series allowing the empirical
head-to-head study of the diagnostic usefulness of biomarkers
Table 1
Examination, biomarker, and pertinent reading tools in this study
Examination Biomarker Reading tool
Structural MR Medial temporal
atrophy (MTA)
Traditional read
Visual Rating Scale [12]
Manual hippocampal
M. Bocchetta et al. / Alzheimer’s & Dementia- (2014) 1-12 3are still pending, this study investigated the perception among
leading dementia researchers of diagnostic usefulness in pa-
tients with MCI assessed in the memory clinics of the EADC
centers with a suspected dementing disorder. This study has
been conceived and carried out by theDiseaseMarkers Special
Interest Group of the EADC.volumetry
FDG-PET Temporoparietal (TP)
and posterior cingulate
(PC) hypometabolism
Traditional read
Statistical maps [48,49]
Scalar metrics [39,40]
CSF Ab40, Ab42, Ab42:Ab40,
tau, phospho-tau
ELISA [50]
Amyloid-PET Cortical amyloid uptake Statistical maps [48]
Structured visual
assessment [11]
Abbreviations: MR, magnetic resonance; FDG, fluorodeoxyglucose;
PET, positron emission tomography; CSF, cerebrospinal fluid.
NOTE. Traditional read is subjective expert judgment based on unstruc-
tured visual assessment of black and white or colored maps. The structured
visual assessment refers to the interpretation of the image based on detailed,
clear and specific instruction. Statistical maps refer to a parametric z-score
image, derived by comparing each image on a pixel-by-pixel basis with a
normative reference database. Scalar metrics refer to an automated sum-
mary measure of Alzheimer’s disease (AD)-related hypometabolism based
on the comparison of individual images with a normative reference data set
in a predefined AD mask.2. Methods
The EADC is a network of 63 European centers of clin-
ical and biomedical research excellence working in the field
of AD (http://www.eadc.info/sito/pagine/home.php). It aims
at increasing the scientific understanding of AD and at devel-
oping therapy for AD symptoms.
An online questionnaire (12 items, see Appendix) as-
sessed: (i) clinical duties of responders (six items); (ii) avail-
ability and frequency of use of biomarker examinations (i.e.
MR, FDG-PET, amyloid-PET, CSF measurements) in pa-
tients with MCI (four items); (iii) the incremental diagnostic
value of biomarkers (one item), and (iv) diagnostic confi-
dence for the diagnosis of prodromal AD or MCI due to
AD (clinical vignette, one item). The questionnaire was
made accessible to EADC memory clinics from November
8 to December 10, 2012. Items 1 to 6 regarded the re-
sponder’s details about his or her specialty, institution, coun-
try, role in the EADC memory clinic and number of new
MCI patients consulted in a typical month. Item 7 investi-
gated the frequency of use of the biomarkers; items 8 and
10 investigated whether the biomarkers are used to support
the diagnosis and which of them are included into the clin-
ical report; whereas item 9 asked to specify the kind of
tool/scale used for the assessment of imaging markers.
Item 11 asked to rate on a five-point Likert scale the addi-
tional diagnostic value of each biomarker on top of clinical
and magnetic resonance assessment; item 12 presented a
clinical vignette and asked to rate the diagnostic confidence
on a five-point Likert scale, on the basis of abnormality of
the biomarkers (alone or combined).
Responders were required to be clinically qualified psy-
chologists/physicians who are actively involved in the clin-
ical management and diagnosis of patients. Only one
responder was allowed per centre. When more than one
completed questionnaire was received from a centre, an-
swers were compounded by the coordinators of this study
at IRCCS Fatebenefratelli in Brescia, and the result was vali-
dated with the site PI.
Table 1 summarizes the examinations, biomarkers, and
pertinent reading tools investigated in this study. It should
be noted thatwhat is referred to as “traditional read” for struc-
tural MR and FDG-PET differed from the “structured visual
assessment” for the amyloid-PET.The former refers to thevi-
sual assessment made by a radiologist who based his or her
interpretation using a reference of normality developed on
the basis of his or her own experience. The latter refers to a
structured assessment, for which image interpretation is
based on detailed, clear, and specific instruction [11].The regional division of Europe is based on United
Nation definition (http://unstats.un.org/unsd/methods/m49/
m49regin.htm#europe) and the estimated population of
each Country is based on http://epp.eurostat.ec.europa.eu/
portal/page/portal/eurostat/home/, as of 01/01/2012.
Answers to the questionnaires were analyzed using SPSS
software version 12.0 (SPSS Inc., Chicago, IL, USA). We
used Mann-Whitney non-parametric U-test to compare
ordinal scores between groups of responders (i.e. those
who “never” or “rarely” use the biomarker and those who
“regularly”, “frequently”, or “always” use it). We used
Spearman rank correlation to measure the strength of the as-
sociation of diagnostic confidence and judgment of addi-
tional diagnostic value with the actual frequency of
biomarker use and features of the responders (age, sex,
and years of clinical experience with AD). The level of sig-
nificance was set at P , .05.3. Results
3.1. Responders’ features
Thirty-seven out of 63 EADC centers participated in our
survey (participation rate 59%). Figure 1 shows the
geographic distribution of responding and non-responding
centers. Most responders were located in Western (41%),
Southern (32%), and Northern Europe (24%). Only one cen-
ter was located in Eastern Europe (3%). As expected, the
number of responder centers in a country correlated with
its estimated population (Spearman’s r 5 .920, P , .005),
under the hypothesis that if there is a bigger population
then there will be more centers by demand of the population
and thus likely more to respond.
Fig. 1. Geographical distribution of the 37 European Alzheimer’s Disease Consortium (EADC) centers taking part to this study (in green). In red the EADC
centers that did not fill in the questionnaire: Belgium (Antwerp, Leuven); Finland (Helsinki); France (Montpellier, Nice, Paris, Toulouse, Tours); Germany (Er-
langen, Goettingen, Ulm); Italy (Bari); Norway (Oslo); Poland (Lodz,Warsaw); Romania (Bucharest); Serbia (Belgrade); Spain (Barcelona, Barcelona,Madrid,
Pamplona); The Netherlands (Amsterdam); United Kingdom (Bristol, London, London, Manchester).
Table 2
Imaging examinations and reading tools used for the assessment of patients
with MCI in EADC centers
Imaging
examination
Clinical
report Reading tool n/total %
Structural MR Not included 4/37 11
included 33/37 89
Visual Rating Scale [12] 20/33 61
Manual hippocampal 1/33 3
M. Bocchetta et al. / Alzheimer’s & Dementia- (2014) 1-124Responders’ specialties were Neurology (46%), Geriat-
rics (22%), Psychiatry (16%), Geriatric Psychiatry (11%),
and others (Neuropsychiatry/Neuropsychology) (5%).About
two thirds of responders (65%) were the lead of a memory
clinic with administrative duties, 16% were leads without
administrative duties, and 19% worked as staff members.
3.2. Clinical role
All responders were involved in the delivery of clinical
consultations to persons with MCI. In a typical month, the
largest number of responders (43%) usually consulted up
to 10 new patients with MCI; 38% 11–20 new patients,
14% 21–40 new patients, and only 2 (5%) more than 40
new patients.
3.3. Use of biomarkers and reading tools
volumetry
Only traditional read 12/33 36
FDG-PET Not included 9/29 31
included 20/29 69
Statistical maps [48,49] 4/20 20
Scalar metrics [39,40] 2/20 10
Only traditional read 14/20 70
Amyloid-PET Not included 9/14 64
included 5/14 36
Statistical maps [49] 1/5 20
Structured visual
assessment [11]
4/5 80
Abbreviations: MR, magnetic resonance; FDG, fluorodeoxyglucose;
PET, positron emission tomography.
NOTE. The denominator is the number of centers that used the biomarker
disaggregated by inclusion of the biomarker result in the clinical report.
More than one reading tool was accepted.3.3.1. Imaging biomarkers
All responders (100%) had access to (i.e. patients could
potentially undergo) structural MR, 78% FDG-PET, and
38% amyloid-PET. Thirty-four responders (92%) used im-
aging to support their etiological diagnosis of MCI, and 33
(89%) included the results of the marker assessment into
the clinical report for the patient or the primary care physi-
cian. Table 2 shows imaging examinations and reading tools
that were typically included in clinical reports. Considering
all reported examinations, the most frequently used tools
were visual rating for MR (61%) (i.e. Scheltens’s MTA scale
[12]); the traditional read for FDG-PET (70%); and struc-
tured visual assessment for amyloid-PET (80%) [11]. Eigh-teen percent (6/33) of responders rated cerebrovascular
disease on MR with a number of different structured visual
scales such as Fazekas’s [13], Wahlund’s [14], and Pasqu-
ier’s [15].
Five responders reported the use of perfusion SPECT,
which was assessed with the traditional visual read by four
M. Bocchetta et al. / Alzheimer’s & Dementia- (2014) 1-12 5and with Statistical Parametric Mapping by one. Three
responders reported the use of computed tomography–no
specific reading tool or scale was reported.
All of the 33 clinicians who included, if performed, at
least one imaging marker into the clinical report, included
MR: 27% of them includedMR alone, but the largest propor-
tion (39%) included MR together with FDG-PET. Only five
centers (15%) included all neuroimaging examinations (i.e.
MR, FDG-PET or SPECT, and amyloid-PET).
3.3.2. CSF Biomarkers and genotype
Thirty-one responders (84%) used CSF markers and 21
(68%) of them included the CSF results in the clinical report.
Of these 21, 19 (91%) included Ab42, 19 (91%) included to-
tal tau and phospho-tau (that were always measured
together), and in 33% of these centers tau markers were
measured combined with Ab42, whereas eight (38%)
included the ratio Ab42:Ab40, whereas only six (29%)
included Ab40. Eight centers (38%) included APOE geno-
type. Only two centers (10%) included all six measures
(Ab42, Ab40, Ab42:Ab40, phospho-tau, total tau, and
APOE genotype) in the clinical report.3.4. Frequency of biomarker use
Figure 2 shows that 62% of responders always used MR
(i.e. for more than 80% of patients), which is the same per-
centage of responders who never used amyloid-PET. Forty-
nine and 40% of responders respectively only rarely used
FDG-PET and CSF biomarkers (i.e. in less than 10% of pa-
tients). Structural MR was prescribed for almost all MCI pa-
tients; lumbar puncture and CSF biomarker assessment were
the second most prescribed procedure (84%), followed by
FDG-PET (78%) (Figure 2). The distributions of frequency
for MR and amyloid-PET were significantly different from
the ones of any other biomarker (P , .001, on Mann-
Whitney U-test), whereas CSF did not significantly differ
from FDG-PET (P 5 .281).Fig. 2. Frequency of biomarker use in the assessment of patients with mild cognit
ters. Values are presented as % and number of the 37 participating EADC centers.
headings of the table correspond to x-axis points on the graph. FDG, fluorodeoxy3.4.1. Combinations of biomarkers
We found that 13 centers (35%) assessed all four core
biomarkers: MTA on MR (TP-PCC hypometabolism or
hypoperfusion on FDG-PET OR SPECT), CSF Ab/tau,
and cortical uptake on amyloid-PET. Eighteen centers
(49%) assessed at least one neuronal injury (MTA on
MR [TP-PCC hypometabolism or hypoperfusion on
FDG-PET OR SPECT] or CSF tau) and one amyloidosis
biomarker (CSF Ab or cortical uptake on amyloid-PET);
four (11%) assessed only neuronal injury biomarkers;
and two (5%) assessed only the structural biomarker
(MTA on MR).3.5. Incremental diagnostic value
Figure 3 shows responders’ judgments of the diagnostic
valueofbiomarkers in addition to clinical andMRassessment.
Sixty percent of responders believed that CSF biomarkers
have “great” to “decisive” incremental diagnostic value, while
the respective figures were 43% and 46% for amyloid-PET
and FDG-PET. The distributions of the ordinal scores of judg-
ment were not significantly different (for all pairs of
biomarker comparison, P  .21 on Mann-Whitney U-test).
If responders are divided up according to frequency of
biomarker use (“never or rarely” vs. “regularly, frequently
or always”, see Figure 2) responders who routinely used
FDG-PET regarded this biomarker had greater added value
than those who used it less often (P 5 .009 on Mann-
Whitney U-test). The frequency of CSF biomarker or
amyloid-PET use did not affect the judgment of usefulness
(P 5 .11 and P 5 .75 on Mann-Whitney U-test). These re-
sults were confirmed in a correlation analysis where fre-
quency of biomarker use and judgment of diagnostic
usefulness were treated as ordinal variables (FDG-PET:
Spearman’s r 5 .457, P 5 .004; CSF Ab/tau: r 5 .272,
P 5 .104; amyloid-PET: r 5 .147, P 5 .385). We have
also investigated the diagnostic confidence of amyloid-
PET in those responders who frequently used CSF andive impairment in European Alzheimer’s Disease Consortium (EADC) cen-
% reported in the graph corresponds to the one reported in the cells. Column
glucose; PET, positron emission tomography; CSF, cerebrospinal fluid.
Fig. 3. European Alzheimer’s Disease Consortium (EADC) centers’ judgment of the incremental diagnostic value of biomarkers in the assessment of mild
cognitive impairment patients on top of clinical assessment and magnetic resonance imaging. The black dotted line denotes those centers who never or rarely
use the biomarker, while the black straight line those who used regularly, frequently or always (see Fig. 2). The number of responding centers is reported in the
upper right corner of each graph. The ordinal score distribution of the two groups is significantly different only for FDG-PET, with frequent users assigning
greater diagnostic value. CSF, cerebrospinal fluid; PET, positron emission tomography; FDG, fluorodeoxyglucose.
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Supplementary Material, Figure S1).
We did not find any significant relationship between the
incremental diagnostic value of FDG-PET and reading pro-
cedure (traditional reading and quantitative tools; Spear-
man’s r 5 .197, P 5 .405), nor of reading tools between
the groups who “never or rarely used” and those who
“routinely used” (P 5 .503 on Mann-Whitney U-test).
When considering only centers that routinely used the perti-
nent biomarkers (black straight line), the modal value was
“Greatly Significant” for all biomarkers (50% for CSF and
for amyloid, and 73% of centers for FDG-PET). We found
that for centers that did not assess routinely amyloid and
FDG-PET (black dotted line), the modal value for these
two markers was “Moderately Significant”, thus lower.
Moreover, amyloid and FDG-PET were considered as not
adding any diagnostic value by 19% and 4% of clinicians,
respectively, who did not frequently use them (P 5 .848
on Mann-Whitney U-test). Moreover no significant correla-
tions between incremental diagnostic value and age, sex or
years of clinical experience with AD of responders were
found (see Table S1, Supplementary Material).3.6. Diagnostic confidence (clinical vignette)
Table 3 indicates that confidence with MCI diagnosis on
the basis of MTA alone was the lowest (P 5 .019 vs. TP-
PC hypometabolism alone, P5 .01 vs. abnormal CSF alone,
P 5 .026 vs. abnormal amyloid-PET alone, and P , .00001
vs. the combination of one amyloid marker and one neuronal
injury marker). Diagnostic confidence was not different
among abnormal FDG-PET, CSF Ab/tau, and amyloid-
PET biomarkers considered alone, but it was significantly
lower than the combination of amyloid and neuronal injury
markers (P 5 .004, P 5 .008, and P 5 .016, on Mann-
Whitney U-test).
We did not find any significant correlation between diag-
nostic confidence and the frequency of biomarker use for any
of the biomarkers (MTA on MR: r5 .077, P5 .655; TP-PChypometabolismonFDG-PET:r5 .140,P5.533; abnormal
CSFAb/tau: r52.078, P5 .724, abnormal amyloid-PET:
r5 .076, P 5 .872, on Spearman test). Moreover no signif-
icant correlations between diagnostic confidence and age,
sex, or years of clinical experience of responders were found
(see Table S2, Supplementary Material).4. Discussion
This was a survey of EADC centers on the reported
use and perceptions of usefulness of AD biomarkers
for the etiological diagnosis of MCI. The centers
included in this survey currently use some biomarkers
for the etiological diagnosis of MCI. Responders largely
agreed that a combination of amyloidosis and neuronal
injury biomarkers was the most convincing in vivo signa-
ture of AD. Interestingly, it seems that EADC centers
were pretty confident in the newer biomarkers (CSF
and amyloid-PET) than in the most frequently used
biomarker (MTA).
Consistent with common practice, among the 37 respond-
ing centers structural MR was the most frequently used tech-
nical examination in the evaluation ofMCI patients, but it also
was the one perceived to contribute the least to diagnostic con-
fidence. This apparent contradiction can be explained by struc-
tural imaging being regarded as mandatory at least once in the
assessment of patients with cognitive impairment, with the
aim to exclude intracranial pathology [16,17]. Moreover,
MR is widely available and non-invasive, and thus practical.
The poor contribution to diagnostic confidence might be due
to MR being usually rated with traditional or visual
approaches, inherently open to subjective interpretation,
only one centre used the more accurate fully quantitative
hippocampal volumetry. However, the time and effort
required is not trivial, accounting for its exceptional clinical
use. The future availability of well-validated automated
methods might help the dissemination of this biomarker to
the clinical routine. Alternatively, because MTA becomes
abnormal late in the disease process [18], it may lack
Table 3
Clinical vignette: physicians’ diagnostic confidence. Values are presented as % of responders (P-value denotes significance at Mann-Whitney U-test)
Difference in perceived strength of diagnostic confidence versus:
TP and PC
hypometabolism
alone
Abnormal
CSFAb and
tau alone
Abnormal
amyloid
PET alone
At least one
abnormal amyloid 1
one abnormal
neuronal injurymarker
Medial temporal
atrophy alone,
n 5 37
P 5 .019 P 5 .010 P 5 .026 P , .00001
TP and PC
hypometabolism
alone, n 5 32
– P 5 .737 P 5 .771 P 5 .004
Abnormal CSF Ab
and tau alone,
n 5 35
– – P 5 .988 P 5 .008
Abnormal amyloid
PET alone, n5 26
– – – P 5 .016
(Continued )
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Table 3
Clinical vignette: physicians’ diagnostic confidence. Values are presented as % of responders (P-value denotes significance at Mann-Whitney U-test)
(Continued )
Difference in perceived strength of diagnostic confidence versus:
TP and PC
hypometabolism
alone
Abnormal
CSFAb and
tau alone
Abnormal
amyloid
PET alone
At least one
abnormal amyloid 1
one abnormal
neuronal injurymarker
At least ONE
abnormal
amyloid 1 ONE
abnormal
neuronal
injury marker,
n 5 36
– – – –
Abbreviations: TP, temporoparietal; PC, posterior cingulate; CSF, cerebrospinal fluidx; PET, positron emission tomography.
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known to lack specificity, as it can be present in non-AD forms
of dementia, like vascular dementia [19,20], semantic
dementia [21], Parkinson’s dementia [20], and frontotemporal
lobar degeneration [22]. Interestingly, EADC centers seem to
endorse the notion that the amyloid cascade stays at the core of
the pathophysiology of AD.
Among responding centers, CSF biomarkers are much
less frequently used than MR, consistently with the rela-
tively poor acceptance of lumbar puncture by patients in
many European countries. This study extends and confirms
the data about the CSF use reported by a former survey
among EADC centers [23]. However, the participants of
the present study perceived CSF assays as having greatly
significant incremental diagnostic value over MR and clin-
ical assessment. This was the opinion regardless of actual
use, and the impact on confidence was significant even
when used in isolation. This is in line with the literature,
showing that CSF Ab42 or Ab42/Ab40 ratio in combina-
tion with total tau and phospho-tau may be useful to iden-
tify AD with sensitivity and specificity values up to 95%
[24]. The pattern of low Ab42 and high total tau and
phospho-tau has been referred to as the “AD signature”
[25–27].
By analogy to CSF biomarkers, hypometabolism on
FDG-PET was also less frequently used than MR, which is
understandable in view of its relatively high costs (i.e.
1000–2000 euros per scan). An interesting finding is that
the judgment of the incremental diagnostic value of FDG-
PET varied according to the frequency of its use. Responders
who routinely used FDG-PET assigned greater incremental
diagnostic value than non-users – an added value that was
perceived greater than that of CSF biomarkers. Although
the association was not affected by the reading procedure(“traditional visual reading” or “quantitative tool”), a
considerable amount of evidence indicates that automated
quantitative tools are more accurate to detect the AD pattern
of cortical hypometabolism than traditional readouts
[28–30] and attenuate the “beginner effect” [29]. Another
possible explanation is that FDG-PET requires experience
to be of value, in contrast to CSF, which uses very simple
cut-off values.
Not surprisingly, amyloid-PET was the least popular
examination among responding centers, due to its still
low availability in clinical centers, low specificity and
high associated costs. Amyloid tracers were recently
approved by both FDA and EMA [31–33] for use in
diagnostic assessment, thus their use in the clinic will
probably increase. In agreement with the literature,
showing that amyloid-PET provides similar or comple-
mentary information as CSF Ab42 assays [34,35], the
perception of added diagnostic value of responders
was similar to the latter. However, whether amyloid-
PET and CSF Ab42 assays provide redundant or com-
plementary information, is an issue under active investi-
gation.
Among responding centers, the most widely used
reading tool for all imaging biomarkers was structured or
unstructured visual readouts. Although this is inevitable
in the case of amyloid imaging where the only FDA- and
EMA-approved procedure is structured visual rating, a
number of automated or semiautomated tools are available
for structural MR and FDG-PET [36–40]. However,
despite their demonstrated superiority over visual
assessments [28–30,41,42], these more quantitative
measures are used by a minority of centers. We argue
that scientific societies should engage in an active
campaign to promote their use, once properly validated,
M. Bocchetta et al. / Alzheimer’s & Dementia- (2014) 1-12 9in cognitively impaired patients undergoing assessment for
suspected AD.
A sizable proportion (about one third) of responding
centers was using all core AD biomarkers, and about
half used at least one biomarker of neuronal injury and
one of amyloidosis. Unsurprisingly, in the clinical
vignette the highest diagnostic confidence was reported
when biomarkers were available in this combination.
What is notable, however, is the huge gain of confidence
from individual to combined biomarker assessments.
This is in line with published evidence, e.g. the assess-
ment of a panel of biomarkers combined instead of a
biomarker alone (whatever it is) drastically increases
the diagnostic accuracy in MCI and AD patients
[7–10,24,43].
This study has some limitations. First, the participation
of EADC centers to the survey was incomplete. At the
time of this survey, the EADC numbered 63 centers, and
of these 37 (59%) took part to the survey. Although this
proportion is low by epidemiologic standards and is
consistent with a potential selection bias, it must be high-
lighted that even the denominator of the proportion is not
rigorously defined. In fact, participation to the EADC rests
on a set of rather relaxed rules including submitting a
request to the Steering Committee, where entry is subject
to a centre delivering clinical dementia care but is also
involved in clinical research and taking part in regular
EADC semiannual meetings. Thus, even the denominator
is affected by selection bias, supporting the notion that the
37 participating centers are an ultraselected group more
likely to use biomarkers in clinical routine than non-
responding centers. What they likely share is comparable
levels of academic interest in research, and cultural or
operational interest in biomarkers for diagnosis, which
might have prompted their participation. Moreover, it
should be acknowledged a potential site bias: it cannot
be excluded that the 37 responder centers are those
more enthusiastic on biomarkers, more active users,
more interested and therefore more likely to respond to
a survey about these markers than non-responder centers.
However, given the current hot debate on early diagnosis
and the polarization of the field into opposing ideological
positions [44], a selection bias in favor of sites strongly
against biomarkers cannot be ruled out. In addition, it
should be noticed that EADC centers have been actively
involved for more than 10 years in clinical and/or preclin-
ical dementia research and clinical trials. It follows that
the conclusions of this survey may not be generalizable
to any memory clinic with a focus on routine medical
care.
Another study limitation is that here we provided a
clinical vignette with clear-cut positive results, but it
would be interesting also to investigate how often clini-
cians encounter negative, ambiguous or disparate results
for different biomarkers and how they interpret these re-
sults. Further surveys can be launched to assess these is-sues, which would be informative and critical in terms of
clinical applicability of these examinations. Moreover, we
have not addressed the impact on diagnostic confidence of
important modifiers such as age at onset of cognitive dis-
turbances, APOE genotype and co-morbidities, factors
that can alter the certainty of the diagnosis. It is known
that early onset patients with dementia (before age 65)
have greater change of biomarkers than late onset patients
[45,46].
Here we only investigated the reported use of bio-
markers in the context of MCI evaluation, and we did
not collect data on the number of actually performed ex-
aminations. Indeed, in this survey all quantitative data
(numbers and percentages) are based on the 37 respond-
ing sites. Even if it might be objected that this question-
naire yields subjective opinions and findings and not
objective evidence on diagnostic value, it must be re-
marked that currently there is no high quality data avail-
able empirically comparing and combining the different
biomarkers for MCI. These empirical data showing the
added value of the use of biomarkers for early diagnosis
are urgently needed, together with empirical evidence of
early diagnostic disclosure for positive results and a
cost-benefit evaluation of the implementation of these ex-
aminations in clinical practice. As a consequence, we
need guidelines on how and when individual biomarkers
(or a combination of them) should and should not be
used as they represent unnecessary costs, based on demo-
graphic, clinical, logistical and economical variables. The
process of shared decision making [47] might also be
considered as relevant in using biomarkers for the diag-
nosis of MCI due to AD. Last, the current survey was
based on visually rating of amyloid-PET; we anticipate
that quantitative measures of ligand uptake will be
increasingly used in the coming years.
In conclusion, these results suggest that biomarkers
for the etiological diagnosis of MCI are currently used
in a sizable group of selected European memory clinics,
and not only for research purposes. These academic cen-
ters represent a forerunner community of early users
who will soon benefit from current efforts to develop
and validate SOPs for biomarker collection and mea-
surement. However, to be implemented in the clinical
practice for the etiologic diagnosis of MCI, the bio-
markers should be definitely and properly validated
and guidelines for clinical standard of care should be
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1. Systematic review: While validation of the revised
diagnostic criteria for Alzheimer’s disease (AD) is
still awaited and large cases series allowing the
empirical head-to-head study of the diagnostic use-
fulness of AD biomarkers are still pending, this study
investigated the perception among European Alz-
heimer’s Disease Consortium centers of diagnostic
usefulness of biomarkers in patients with mild
cognitive impairment (MCI).
2. Interpretation: Responder centers currently use the
core biomarkers (cerebrospinal fluid Ab/tau levels,
medial temporal atrophy, hypometabolism on fluoro-
deoxyglucose positron emission tomography, FDG-
PET) for the etiological diagnosis of MCI and
largely agreed that a combination of amyloidosis and
neuronal injury biomarkers was a strongly indicative
AD signature.
3. Future directions: The use of biomarkers for the etio-
logical diagnosis of MCI is widespread in the Euro-
pean academic research memory clinics surveyed
here. They represent a forerunner community of
early users who will soon benefit from current efforts
to develop and validate standard operating proce-
dures for biomarker collection and measurement.References
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Figure S1. EuropeanAlzheimer’s Disease Consortium centers’ judgment of the incremental diagnostic value of amyloid-PET in thosewho routinely or not used
the CSF (and vice versa) in the assessment of mild cognitive impairment patients on top of clinical assessment and magnetic resonance imaging. Amyloid-PET-
Left Panel: The black dotted line denotes those centers that never or rarely used the CSF; the black straight line those that used regularly, frequently or always the
CSF. CSF - Right Panel: The black dotted line denotes those centers that never or rarely use the amyloid-PET; the black straight line those that use regularly,
frequently or always the amyloid-PET. For both graphs, the red line denotes the two groups pooled together (see Figure 2). The number of responding centers is
reported in the upper right corner of each graph. PET; positron emission tomography, CSF; cerebrospinal fluid.
Table S1
Correlations between incremental diagnostic value and age, sex, and years
of clinical experience with AD of the responders (P-value denotes
significance on Spearman rank correlation test)
Age Sex
Years of clinical
experience with AD
FDG-PET r 5 2.132,
P 5 .473
r 5 2.231,
P 5 .170
r 5 2.051, P 5 .796
CSF r 5 2.032,
P 5 .861
r 5 2.171,
P 5 .312
r 5 2.069, P 5 .729
Amyloid-PET r 5 .206,
P 5 .258
r 5 2.033,
P 5 .847
r 5 .214, P 5 .275
Abbreviations: FDG; fluorodeoxyglucose, PET; positron emission to-
mography, CSF; cerebrospinal fluid, AD; Alzheimer’s Disease.
Table S2
Correlations between diagnostic confidence and age, sex and years of
clinical experience of the responders (P-value denotes significance on
Spearman rank correlation test)
Age Sex
Years of clinical
experience
with AD
Medial temporal
atrophy ALONE
r 5 .169,
P 5 .354
r 5 2.101,
P 5 .551
r 5 .006,
P 5 .977
TP and PC
hypo-metabolism
ALONE
r 5 2.143,
P 5 .468
r 5 .056
P 5 .760
r 5 2.185,
P 5 .387
Abnormal CSF Ab
and tau ALONE
r 5 2.189,
P 5 .309
r 5 .006,
P 5 .971
r 5 2.336,
P 5 .086
Abnormal amyloid-PET
ALONE
r 5 .142,
P 5 .528
r 5 .253,
P 5 .212
r 5 .225,
P 5 .340
At least ONE abnormal
amyloid 1 ONE
abnormal neuronal
injury marker
r 5 2.014,
P 5 .940
r 5 .015,
P 5 .931
r 5 2.048,
P 5 .810
Abbreviations: TP; temporoparietal, PC; posterior cingulate, CSF;
cerebrospinal fluid, PET; positron emission tomography, AD; Alzheimer’s
Disease.
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